3.9 Article

P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)

Journal

EUROPEAN UROLOGY SUPPLEMENTS
Volume 11, Issue 5, Pages 230-231

Publisher

Elsevier BV
DOI: 10.1016/s1569-9056(13)60481-9

Keywords

-

Categories

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available